Advertisement
Advertisement
ARDX
Ardelyx, Inc.
3.78
USDSponsored
+0.04
+1.07%
Aug 25, 15:56 UTC -4
Closed
After-Market
3.81
+0.03
+0.79%
ARDX Earnings Reports
Positive Surprise Ratio
ARDX beat 26 of 43 last estimates.
60%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$134.13M
/$0.00
Implied change from Q2 26 (Revenue/ EPS)
+10.97%
/-100.00%
Implied change from Q3 25 (Revenue/ EPS)
+21.58%
/--
Ardelyx, Inc. earnings per share and revenue
On Aug 06, 2026, ARDX reported earnings of -0.07 USD per share (EPS) for Q2 26, missing the estimate of -0.06 USD, resulting in a -7.03% surprise. Revenue reached 120.88 million, compared to an expected 123.43 million, with a -2.07% difference. The market reacted with a -17.86% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of 0.00 USD, with revenue projected to reach 134.13 million USD, implying an decrease of -100.00% EPS, and increase of 10.97% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Ardelyx, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Ardelyx, Inc. reported EPS of -$0.07, missing estimates by -7.03%, and revenue of $120.88M, -2.07% below expectations.
How did the market react to Ardelyx, Inc.'s Q2 2026 earnings?
The stock price moved down -17.86%, changed from $4.87 before the earnings release to $4.00 the day after.
When is Ardelyx, Inc. expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for Ardelyx, Inc.'s next earnings report?
Based on --
analysts, Ardelyx, Inc. is expected to report EPS of -- and revenue of $134.13M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement